Purevax RCPCh FeLV (Attenuated feline rhinotracheitis herpesvirus...) - QI06AX
Updated on site: 09-Feb-2018
|Medication name:||Purevax RCPCh FeLV|
|Substance:||Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline Calicivirosis antigens (FCV 431 and G1 strains), attenuated Chlamydophila felis (905 strain), attenuated feline panleucopenia virus (PLI IV), FeLV recombinant canarypox viru|
- What is Purevax RCPCh FeLV?
- How does Purevax RCPCh FeLV work?
- How has Purevax RCPCh FeLV been studied?
- What benefit has Purevax RCPCh FeLV shown during the studies?
- What is the risk associated with Purevax RCPCh FeLV?
- What are the precautions for the person who gives the medicine or comes into contact with the animal?
- Why has Purevax RCPCh FeLV been approved?
PUREVAX RCPCH FELV
EPAR summary for the public
This document is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use. This document cannot replace a
What is Purevax RCPCh FeLV?
Purevax RCPCh FeLV is a vaccine containing the following active substances:
•attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain),
•inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains),
•attenuated Chlamydophila felis (905 strain),
•attenuated feline panleucopenia virus (PLI IV),
•feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
Purevax RCPCh FeLV is a lyophilisate
What is Purevax RCPCh FeLV used for?
Purevax RCPCh FeLV is used to vaccinate cats from the age of 8 weeks against the following diseases:
•feline viral rhinotracheitis (a
•feline calicivirosis (a
•feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus),
•feline leukaemia (an illness affecting the immune system caused by a retrovirus).
The vaccine helps to reduce the symptoms of the diseases. It also helps to reduce viral excretion in case of calicivirus infection. It can also prevent death due to panleucopenia and prevent FeLV from remaining in the blood.
After Purevax RCPCh FeLV has been made up, 1 ml is injected under the skin. The first injection should be given in cats aged at least eight weeks, with a second injection three to four weeks later. If the cat has high levels of antibodies inherited from the mother, the first vaccination should be delayed until 12 weeks of age. The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis, calicivirosis, chlamydiosis and feline leukaemia, and every three years for panleucopenia.
How does Purevax RCPCh FeLV work?
Purevax RCPCh FeLV is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against diseases. Purevax RCPCh FeLV contains small amounts of weakened or killed viruses and bacteria that cause the diseases listed above, as well as two genes from the FeLV called env and gag, which have been inserted into another vector (carrier) virus called canarypox using ‘recombinant DNA technology’. The canarypox viruses do not spread or multiply in the cat but they do produce proteins from the FeLV genes. When a cat is given the vaccine, the immune system recognises the weakened or killed viruses, the FeLV proteins, and the weakened bacteria as ‘foreign’ and makes antibodies against them. In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses or bacteria. The antibodies will help to protect against the diseases caused by these viruses or bacteria. When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.
How has Purevax RCPCh FeLV been studied?
The effectiveness of Purevax RCPCh FeLV has been studied in several trials in laboratory conditions where cats were vaccinated and infected with virulent herpesvirus, calicivirus, C. felis, parvovirus or leukaemia virus. In the field, the studies of Purevax RCPCh FeLV looked at the basic vaccination schedule (2 injections
What benefit has Purevax RCPCh FeLV shown during the studies?
In laboratory conditions, Purevax RCPCh FeLV was demonstrated to provide protection against the diseases listed above. In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus, calicivirus infection, and feline panleucopenia viruses. It was not possible to detect a rise in antibodies against C. felis because of high levels of antibodies in the cats at the beginning of the study. In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus, calicivirus infection, feline panleucopenia and C. felis remained stable at a high level or increased slightly.
What is the risk associated with Purevax RCPCh FeLV?
Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days. There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks. For a full list of the
What are the precautions for the person who gives the medicine or comes into contact with the animal?
In case of accidental
Why has Purevax RCPCh FeLV been approved?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RCPCh FeLV exceed the risks for the active immunisation of cats aged eight weeks or older against the diseases listed above, and recommended that Purevax RCPCh FeLV be given a marketing authorisation. The
Other information about Purevax RCPCh FeLV:
The European Commission granted a marketing authorisation valid throughout the European Union for Purevax RCPCh FeLV to MERIAL on 23 February 2005.
This summary was last updated on 25 January 2008.